Prosecution Insights
Prosecution Insights
22 pending office actions • 16 art units • 21 examiners • 0 of 22 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (9%) |
| §103 only | 3 (14%) |
| §102 only | 3 (14%) |
| §112 only | 3 (14%) |
| Double-patenting only | 2 (9%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 8 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 2 | 31.7% | +20.3% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.6% | +39.6% |
| NEAGU, IRINA | 1 | 46.8% | +57.4% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.9% | +41.5% |
| LEE, ANDREW P | 1 | 48.4% | +23.3% |
| GILL, RACHEL B | 1 | 65.4% | +28.0% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| SABILA, MERCY HELLEN | 1 | 57.6% | +45.9% |
| KELLY, ROBERT M | 1 | 73.8% | +24.8% |
| MCCORMICK, CATHERINE LYNN | 1 | 48.8% | +35.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 2d overdue |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | GILL, RACHEL B | 20d |
| 17768896 | EFFICIENT RNA SWITCHES AND RELATED EXPRESSION SYSTEMS | YAMASAKI, ROBERT J | 22d |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 65d |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | — |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | — |
| 18546750 | SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B | SABILA, MERCY HELLEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | ROBINSON, MIKHAIL O'DONNEL | 26d overdue |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 2d overdue |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | GILL, RACHEL B | 20d |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | — |
| 18810305 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | — |
| 18532609 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | SULLIVAN, STEPHANIE LAUREN | — |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1627 | 3 |
| 3991 | 2 |
| 1654 | 2 |
| 1638 | 2 |
| 1699 | 2 |
| 1637 | 1 |
| 1629 | 1 |
| 1691 | 1 |
| 1671 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | 3991 | DP | Non-Final OA | — | Pending | Mar 18, 2025 |
| 18810305 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | 3991 | DP | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18532609 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | SULLIVAN, STEPHANIE LAUREN | 1637 | §103§112DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | 1629 | §102§103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102 | Non-Final OA | 26d overdue | Pending | Nov 08, 2023 |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | 83d | Pending | Nov 08, 2023 |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | GILL, RACHEL B | 1671 | §101§102§112Other | Non-Final OA | 20d | Pending | Oct 10, 2023 |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18546750 | SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B | SABILA, MERCY HELLEN | 1654 | §103§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | 2d overdue | Pending | Jun 01, 2023 |
| 18315383 | SONOGENETIC STIMULATION OF CELLS EXPRESSING A HETEROLOGOUS MECHANOSENSITIVE PROTEIN | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Non-Final OA | — | Pending | May 10, 2023 |
| 18305292 | COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | — | Pending | Apr 21, 2023 |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | FLINDERS, JEREMY C | 1684 | §112 | Final Rejection | 10d overdue | Pending | Apr 21, 2023 |
| 18044260 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | JARRELL, NOBLE E | 1699 | §101§102§112 | Non-Final OA | — | Pending | Mar 07, 2023 |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Non-Final OA | 65d | Pending | Nov 03, 2022 |
| 17918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | 30d overdue | Pending | Oct 12, 2022 |
| 17915559 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | STOCKTON, LAURA LYNNE | 1626 | §102§112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17782560 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | HA, JULIE | 1654 | §112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17826660 | SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | OTTON, ALICIA L | 1699 | §102 | Final Rejection | — | Pending | May 27, 2022 |
| 17768896 | EFFICIENT RNA SWITCHES AND RELATED EXPRESSION SYSTEMS | YAMASAKI, ROBERT J | 1657 | §103§112 | Non-Final OA | 22d | Pending | Apr 14, 2022 |
| 17753139 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | HSU, GRACE CHING | 1627 | §112 | Non-Final OA | — | Pending | Feb 21, 2022 |
| 17419904 | THERAPEUTIC COMBINATIONS AS ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE | IVANOVA, SVETLANA M | 1627 | §103 | Final Rejection | 11d overdue | Pending | Jun 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial